Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients

TerminatedOBSERVATIONAL
Enrollment

88

Participants

Timeline

Start Date

December 21, 2022

Primary Completion Date

September 12, 2025

Study Completion Date

September 12, 2025

Conditions
Lung Diseases, Interstitial
Interventions
DRUG

Nintedanib

Nintedanib

Trial Locations (21)

10676

Private physician, Athens

11362

Private physician, Athens

11527

"G. Gennimatas General Hospital of Athens", Athens

"Ippokration General Hospital of Athens", Athens

"Laiko General Hospital of Athens", Athens

11634

Private physician, Athens

12462

"ATTIKON University General Hospital", Athens

14561

"KAT General Hospital", Athens

17121

Private physician, Nea Smirni, Athens

26504

Private physician, Pátrai

University General Hospital of Patra, Pátrai

41222

Private physician, Larissa

41334

University General Hospital of Larisa, Larissa

45332

Private physician, Ioannina

45500

University General Hospital of Ioannina, Ioannina

54622

Private physician, Thessaloniki

54642

"Hippokration General Hospital of Thessaloniki", Thessaloniki

57010

"G. Papanikolaou General University of Thessaloniki", Thessaloniki

"Clinic Agios Loukas", Thessaloniki

71003

University General Hospital of Heraklion, Heraklion

71110

University General Hospital of Heraklion, Heraklion

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05503030 - Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients | Biotech Hunter | Biotech Hunter